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Abstract: Cystinosis is an autosomal recessive inherited lysosomal storage disease. It is 
characterized by generalized proximal tubular dysfunction known as renal Fanconi syndrome and 
causes end-stage renal disease by the age of about 10 years if left untreated. Extrarenal organs are 
also affected, including the thyroid gland, gonads, pancreas, liver, muscle, and brain. Treatment 
consists of administration of cysteamine, resulting in depletion of cystine that is trapped inside 
the lysosomes. Since cysteamine has a short half-life, it should be administered every 6 hours. 
Recently, a new delayed-release formulation was marketed, that should be administered every 
12 hours. The first studies comparing both cysteamine formulations show comparable results 
regarding white blood cell cystine depletion (which serves as a measure for cystine accumulation 
in the body), while a slightly lower daily dose of cysteamine can be used.
Keywords: cystinosis, cysteamine, delayed-release, immediate-release
Introduction
Cystinosis is a lysosomal storage disease. It is inherited in an autosomal reces-
sive manner and is caused by mutations in the CTNS gene, which is located on 
chromosome 17p13.1 These mutations cause intralysosomal cystine accumulation in 
cells throughout the body. Today, over 100 pathogenic mutations are known to cause 
cystinosis. The most frequent mutation found in western Europe is a large deletion 
of 57,257 base pairs.2
CTNS encodes the lysosomal cystine transporter cystinosin, which is a 367 amino 
acid lysosomal membrane protein, with seven transmembrane domains. Cystinosin is a 
proton-cystine cotransporter, coupling the excretion of both cystine and protons out of 
the lysosome. Protons are carried back into the lysosome by H+-ATPase.3 Besides the 
cystinosin that is localized on the lysosomal membrane, a second isoform exists due 
to alternative splicing of CTNS messenger RNA (mRNA). This isoform lacks one of 
the two lysosomal targeting motifs, consists of the amino acid sequence GYDQL, and 
was named cystinosin-LKG (the letters LKG representing its last three amino acids). 
Cystinosin-LKG is localized at the plasma membrane in lysosomes and several other 
organelles, including the Golgi apparatus and the endoplasmic reticulum. Its exact 
function remains unclear; however, it is known to facilitate the transport of cystine in 
an acidic environment, just like its counterpart cystinosin.4
Cystinosis has an incidence of one per 100,000–200,000 live births, and in suspected 
cases, the diagnosis can be confirmed by measuring white blood cell (WBC) cystine 
levels and/or by CTNS gene analysis. Three clinical forms of cystinosis can be distin-
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Patients generally present before the age of 12 months 
with polyuria, polydipsia, and failure to thrive caused by 
generalized proximal tubular damage, also known as renal 
Fanconi syndrome. It is characterized by increased urinary 
excretion of several small molecules, including glucose, salts, 
amino acids, and low molecular weight proteins.  Photophobia 
is caused by corneal cystine crystals, which can be recog-
nized by an experienced ophthalmologist from the age of 
12 months.5 Further, several other organs can be involved dur-
ing progression of the disease. These include the thyroid gland 
(hypothyroidism),6 gonads (hypogonadism, azoospermia),7,8 
pancreas (exocrine and endocrine insufficiency),9,10 muscles 
(hypotrophy, swallowing difficulties),11 and the peripheral 
and central nervous systems.11 Late-onset or juvenile neph-
ropathic cystinosis (OMIM 219900) is characterized by the 
same symptoms as infantile cystinosis, but with a disease 
onset mostly after the first decade of life and a slower rate of 
disease progression. In contrast, patients with the ocular form 
of cystinosis (OMIM 219750) only have photophobia due to 
corneal cystine crystals while other organs remain spared. The 
latter two forms of cystinosis are very rare; over 95% of all 
cystinosis patients are diagnosed with the infantile form.5
Treatment with cysteamine
Cysteamine (β-mercaptoethylamine) was first introduced 
as a possible therapeutic agent to treat cystinosis in 1976,12 
and until now has been the only available treatment for the 
disease. After its introduction as a treatment for patients 
with cystinosis, cysteamine was first prescribed in the form 
of cysteamine HCl. Because of the low bioavailability of the 
hydrochloride salt, it was replaced by phosphocysteamine in 
1980.13 In 1994, cysteamine bitartrate (Cystagon®, Mylan 
Pharma, Morgantown, WV, USA) was introduced14 and this 
is currently the most widely used preparation of cysteamine. 
Recently, an enteric-coated preparation of cysteamine bitar-
trate (Procysbi™, Raptor Pharmaceuticals Inc., Novato, CA, 
USA) was approved by the US Food and Drug Administra-
tion and European Medicines Agency for the treatment of 
cystinosis.
Cysteamine uses an unknown transporter to enter the lys-
osome and subsequently breaks the disulfide bond in cystine. 
This leads to formation of cysteine, which leaves the lyso-
some using the cystine transporter, and cysteine- cysteamine 
disulfide, which leaves the lysosome using the PQLC2 
transporter (Figure 1).5,15 Once in the cytosol, cysteine can be 
further metabolized to form glutathione, one of the cell’s most 
potent redox buffers. Indeed, in vitro experiments showed 
that the altered redox status demonstrated in cystinotic cells 
was corrected by administration of cysteamine, thereby 
increasing intracellular glutathione levels.16
One hour after ingestion of cysteamine, the drug’s plasma 























Figure 1 Mechanism of lysosomal cystine depletion by cysteamine. Cysteamine enters the lysosome through an unknown transporter and breaks the disulfide bond in 
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Cysteamine bitartrate in the treatment of cystinosis
at their minimum, followed by a gradual decline in plasma 
cysteamine levels and a gradual increase of WBC cystine 
levels. Both reach their original values around 6 hours after 
ingestion.17 This underscores the importance of a dosing 
regimen in which cysteamine is administered every 6 hours; 
ideally, it should also be administered during the night.18 
Understandably, such a dosing scheme causes a great burden 
in terms of compliance with cysteamine therapy.
Treatment of cystinosis patients with cysteamine is 
further hampered by the side effects of the drug. When 
cysteamine was first prescribed to patients with cystinosis, 
several of them developed hyperthermia, lethargy, and 
rash. However, all of these side effects were reversible after 
the treatment was discontinued, and none of these adverse 
events are noted today since it has become common practice 
to introduce cysteamine at a low dose with a subsequent 
gradual increase over several weeks.19 Gastrointestinal 
complaints are due to increased gastric acid secretion after 
ingestion of cysteamine,20 and thus concomitant use of 
proton pump inhibitors is advised.21 After administration of 
cysteamine, a small amount is metabolized into the volatile 
sulfur compounds methanethiol and dimethylsulfide, causing 
halitosis.22 Recently, eight cystinosis patients were found to 
have new adverse events associated with cysteamine, con-
sisting of bruise-like lesions on the elbows, skin striae, and 
severe bone and muscular pain. Skin biopsies taken from the 
bruise-like lesions showed reactive angioendotheliomatosis 
and alterations in collagen fiber diameter.23 The reactive 
angioendotheliomatosis could be attributed to increase sur-
vival of dermal microvascular endothelial cells after expo-
sure to cysteamine,24 while the collagen fiber abnormalities 
could be the result of a synergistic effect of cysteamine and 
copper deficiency (which was found in all patients identi-
fied as having these side effects) on inhibition of collagen 
cross-linking.25
The newly reported side effects of cysteamine resulted 
in new recommendations regarding dosing. Instead of 
using body weight to calculate the dose of cysteamine 
(50 mg/kg/day, with a maximum of 90 mg/kg/day) it is now 
advised to use body surface area (1.30 g/m²/day, with a 
maximum of 1.95 g/m²/day). This difference in calculation 
method is particularly important in growing children, in 
whom body weight increases faster than body surface area. 
This may lead to higher (potentially toxic) doses when using 
body weight to calculate the daily cysteamine dose, since 
90 mg/kg may exceed 1.95 g/m².23
Despite its side effects and four times daily dosing 
regimen, cysteamine remains the cornerstone of treatment 
for cystinosis and adequate administration of cysteamine 
significantly reduces the rate of progression towards end-stage 
renal disease, and postpones or even prevents the occurrence 
of extrarenal complications.26–29 Hypothyroidism, myopathy, 
pulmonary dysfunction, and diabetes mellitus (caused by pan-
creas insufficiency) occur less frequently in cystinosis patients 
who have been treated with cysteamine for a prolonged period 
of time.27,30 Further, while children with cystinosis show more 
pronounced growth retardation than children with other renal 
diseases, adequate treatment with cysteamine significantly 
improves growth parameters.29,31,32 Nonetheless, most chil-
dren with cystinosis also require treatment with recombinant 
human growth hormone to achieve a final height higher than 
two standard deviations below the mean.29,32
Unfortunately, not all complications of cystinosis are 
delayed by administration of cysteamine. Cysteamine does 
not influence the incidence of primary hypogonadism in male 
patients with cystinosis, nor does it improve delayed puberty. 
Also, male infertility due to azoospermia is not ameliorated 
by adequate treatment with cysteamine.7,8 Further, systemic 
administration of cysteamine does not prevent formation 
of corneal cystine crystals,33 indicating a need for topi-
cal cysteamine eye drops which should be applied several 
times daily. Recently, a new gel formulation of cysteamine 
(Cystadrops®, Orphan Europe, Montluçon, France) was tested 
for its ability to diminish the formation of corneal cystine 
crystals, with better effects and less applications needed 
per day compared with the usual cysteamine hydrochloride 
formulation.34
Other novel treatment strategies
The most promising results with regard to treatment of 
cystinosis without use of cysteamine come from the field of 
stem cell transplantation. In a CTNS−/− mouse model treated 
with wild-type allogeneic bone marrow and hematopoietic 
stem cells, the mice that received a bone marrow graft 
showed better renal function after 4 and 15 months, as well 
as decreased cystine content in a number of tissues, includ-
ing the brain, eyes, heart, kidneys, liver, skeletal muscle, and 
spleen.35,36 However, despite these promising results, tissue 
cystine levels remained higher than those in asymptomatic 
heterozygous carriers, so administration of cysteamine may 
still be warranted.
In addition to bone marrow transplantation, gene therapy 
was also studied in the CTNS−/− mouse model in order to 
minimize the use of immunosuppressive agents, along with 
the risks of rejection and development of graft versus host 
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transduced with the human CTNS complementary DNA 
(cDNA) sequence followed by transplantation into CTNS−/− 
mice. Again, tissue cystine levels were significantly decreased 
after 4 and 8 months, including in the brain, eyes, kidneys, 
liver, muscle, and spleen, but were still higher than those 
after wild-type bone marrow transplantation.37
Prodrugs are under development in order to diminish 
the bad taste and smell of cysteamine and to increase its 
half-life. Several prodrugs of cysteamine have been tested 
in vitro;38,39 however, none are as effective as cysteamine in 




The observation that administration of cysteamine directly 
in the small intestine resulted in higher plasma cysteamine 
levels with a higher area under the curve when compared 
with gastric administration of the drug40 led to development 
of the enteric-coated formulation of cysteamine bitartrate 
(Procysbi). In contrast with the immediate-release formu-
lation of cysteamine bitartrate, this new delayed-release 
formulation can be administered every 12 hours instead of 
every 6 hours.41 The delayed-release formulation consists of 
capsules containing small granules than can be administered 
through a feeding tube. This is important, given that most 
small children with cystinosis require a lot of fluids and 
electrolyte supplements, and thus have feeding tubes that 
are also used for administration of medication.
In a Phase III trial testing the noninferiority of the 
delayed-release formulation, 41 nontransplanted patients 
with cystinosis were randomized to treatment with either 
immediate-release or delayed-release cysteamine bitartrate 
for 3 weeks and then switched to the other formulation for 
a further 3 weeks. The mean difference in WBC cystine 
levels after treatment with the delayed-release formulation 
compared with the immediate-release formulation was 
0.08 nmol ½ cystine/mg protein (95.8% confidence interval 
0.00–0.16), meaning that the primary endpoint of noninfe-
riority was met.42
Interestingly, the average total daily steady-state dose of 
the delayed-release formulation was 82% of the previously 
established incoming dose of the immediate-release formula-
tion,42 indicating that similar results for depletion of WBC 
cystine can be achieved with a slightly lower daily amount of 
cysteamine. In theory, this could result in fewer side effects. 
An early pilot study was conducted comparing the excretion 
of volatile sulfur compounds in four patients after ingestion 
of immediate-release or delayed-release cysteamine bitartrate 
(as part of the crossover Phase III clinical trial). This study 
showed a trend towards a lower area under the curve for dim-
ethylsulfide excretion in all four tested patients after ingestion 
of the delayed-release formulation. However, this trend did 
not reach statistical significance, patient numbers were small, 
and the measured levels of dimethylsulfide remained above 
those that cause halitosis at all time points.43
A long-term study is presently underway using delayed-
release cysteamine bitartrate in cystinosis patients with renal 
Fanconi syndrome and in those who have undergone renal 
transplantation. Again, as part of this study, excretion of vola-
tile sulfur compounds in breath will be measured in a subgroup 
of patients, comparing the levels at study onset when patients 
are treated with the immediate-release formulation and again a 
few months after treatment with the delayed-release formula-
tion. The final results of this study are pending, but preliminary 
data show that dimethylsulfide breath levels again remained 
persistently above the threshold that causes halitosis; however, 
further analysis should determine whether the area under 
the curve is influenced by the delayed-release formulation. 
Previous reports regarding the long-term treatment of two 
cystinosis patients with the delayed-release formulation show 
a good effect on the mean trough WBC cystine level, with 
no deterioration of renal, thyroid, or liver function observed 
during a treatment period of 6 years.44
Prognosis
Overall, the quality of life for patients with cystinosis has 
improved significantly since the early 1980s. Since the use 
of cysteamine to treat cystinosis and the introduction of renal 
replacement therapy in pediatric populations (either through 
dialysis or by renal transplantation), patients with cystinosis 
are increasingly surviving into adulthood, whereas before 
the introduction of cysteamine as a possible treatment for 
cystinosis they generally died from end-stage renal disease 
by around the age of 10 years.27 This increased life expec-
tancy has caused an increase in the number of longer-term 
complications of the disease, that were not noticed in younger 
patients. This increased interest and recognition of longer-
term complications of cystinosis prompted a search for a 
possible treatment for these complications. For instance, male 
infertility due to azoospermia was first described only a few 
years ago, awareness of which has enabled patients to seek 
further treatment options, such as testicular sperm extraction, 
which could open the possibility for male patients to produce 
their own offspring.8 Another example is the severe growth 













































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Cysteamine bitartrate in the treatment of cystinosis
treated more effectively (eg, by improving nutritional and 
electrolyte status, prescribing cysteamine, and administra-
tion of recombinant human growth hormone), today most 
cystinosis patients can reach a final height within the normal 
range,29,32 which further improves their quality of life.
Apart from better recognition and treatment of (late-term) 
complications of cystinosis, better treatment of the disease 
also improves the long-term outcome for the patient. 
 Cystinosis is now more frequently recognized at a young 
age, resulting in more patients being adequately treated 
with cysteamine at a young age. This is very important, 
since early initiation of cysteamine therapy can significantly 
postpone or even prevent complications of the disease, 
including deterioration of renal function, hypothyroidism, 
and myopathy.26–29 However, one of the most important bur-
dens regarding cysteamine therapy is the need to administer 
the drug every 6 hours in order to ensure adequate WBC 
cystine depletion.18 Development of the new delayed-release 
formulation can overcome this problem, which will likely 
improve patient compliance with therapy, resulting in fewer 
long-term complications of cystinosis and improving patient 
life expectancy even further.
It remains uncertain to what degree potential new thera-
pies for cystinosis (including bone marrow transplantation 
and/or gene therapy) will further improve the long-term out-
comes. Although impressive results have been documented 
in the CTNS−/− mouse model, there are as yet no results of 
such treatment in humans.
Conclusion
From 197612 until now, cysteamine has been the only treatment 
available for cystinosis. The advent of cysteamine has signifi-
cantly improved the outcome for patients with cystinosis, as 
have the better recognition and treatment of the complications 
of the disease. New treatment options, such as bone marrow 
transplantation are promising, but are not currently performed 
routinely in humans. Further, although intracellular cystine 
levels in a number of tissues in CTNS−/− mice decrease signifi-
cantly after bone marrow transplantation derived from their 
wild-type litter mates, cystine levels remain above those of 
asymptomatic heterozygous carriers.35,36
Thus, even after bone marrow transplantation, there may 
still be a need for low doses of cysteamine to decrease the 
remaining accumulation of cystine. This indicates a need to 
further improve the treatment of cystinosis with cysteamine. 
In this regard, the new delayed-release formulation of 
cysteamine bitartrate is of importance to improve compliance 
with cysteamine therapy.
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